These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20163245)

  • 41. Gene therapy for type I glycogen storage diseases.
    Chou JY; Mansfield BC
    Curr Gene Ther; 2007 Apr; 7(2):79-88. PubMed ID: 17430128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.
    Flotte TR; Zeitlin PL; Reynolds TC; Heald AE; Pedersen P; Beck S; Conrad CK; Brass-Ernst L; Humphries M; Sullivan K; Wetzel R; Taylor G; Carter BJ; Guggino WB
    Hum Gene Ther; 2003 Jul; 14(11):1079-88. PubMed ID: 12885347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia).
    Kishnani PS; Faulkner E; VanCamp S; Jackson M; Brown T; Boney A; Koeberl D; Chen YT
    Vet Pathol; 2001 Jan; 38(1):83-91. PubMed ID: 11199168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver-directed gene therapy for murine glycogen storage disease type Ib.
    Kwon JH; Lee YM; Cho JH; Kim GY; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Hum Mol Genet; 2017 Nov; 26(22):4395-4405. PubMed ID: 28973635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.
    Nicolson SC; Li C; Hirsch ML; Setola V; Samulski RJ
    J Virol; 2016 Aug; 90(16):7019-7031. PubMed ID: 27147738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency.
    Farah BL; Landau DJ; Sinha RA; Brooks ED; Wu Y; Fung SYS; Tanaka T; Hirayama M; Bay BH; Koeberl DD; Yen PM
    J Hepatol; 2016 Feb; 64(2):370-379. PubMed ID: 26462884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice.
    Clar J; Mutel E; Gri B; Creneguy A; Stefanutti A; Gaillard S; Ferry N; Beuf O; Mithieux G; Nguyen TH; Rajas F
    Hum Mol Genet; 2015 Apr; 24(8):2287-96. PubMed ID: 25561689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose.
    Rossi A; Oosterveer MH; van Dijk TH; Bleeker A; Koehorst M; Weinstein DA; Bakker BM; Derks TGJ
    J Clin Endocrinol Metab; 2024 Jan; 109(2):389-401. PubMed ID: 37690115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.
    Vidal P; Pagliarani S; Colella P; Costa Verdera H; Jauze L; Gjorgjieva M; Puzzo F; Marmier S; Collaud F; Simon Sola M; Charles S; Lucchiari S; van Wittenberghe L; Vignaud A; Gjata B; Richard I; Laforet P; Malfatti E; Mithieux G; Rajas F; Comi GP; Ronzitti G; Mingozzi F
    Mol Ther; 2018 Mar; 26(3):890-901. PubMed ID: 29396266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Development of New Therapy for Glycogen Storage Diseases.
    Sun B; Brooks ED; Koeberl DD
    Curr Gene Ther; 2015; 15(4):338-47. PubMed ID: 26122079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.
    Peden CS; Burger C; Muzyczka N; Mandel RJ
    J Virol; 2004 Jun; 78(12):6344-59. PubMed ID: 15163728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double filtration plasmapheresis for pregnancy with hyperlipidemia in glycogen storage disease type Ia: A case report.
    Wang J; Zhao Y; Chang P; Liu B; Yao R
    World J Clin Cases; 2022 Oct; 10(28):10273-10278. PubMed ID: 36246825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
    Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
    Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.
    Marks WJ; Baumann TL; Bartus RT
    Hum Gene Ther; 2016 Jul; 27(7):522-7. PubMed ID: 26711317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Noninvasive Imaging Reveals Stable Transgene Expression in Mouse Airways After Delivery of a Nonintegrating Recombinant Adeno-Associated Viral Vector.
    Vidović D; Gijsbers R; Quiles-Jimenez A; Dooley J; Van den Haute C; Van der Perren A; Liston A; Baekelandt V; Debyser Z; Carlon MS
    Hum Gene Ther; 2016 Jan; 27(1):60-71. PubMed ID: 26567984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors.
    Conlon TJ; Mah CS; Pacak CA; Rucker Henninger MB; Erger KE; Jorgensen ML; Lee CC; Tarantal AF; Byrne BJ
    Hum Gene Ther Clin Dev; 2016 Dec; 27(4):152-159. PubMed ID: 27855487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome editing using
    Arnson B; Kang HR; Brooks ED; Gheorghiu D; Ilich E; Courtney D; Everitt JI; Cullen BR; Koeberl DD
    Mol Ther Methods Clin Dev; 2023 Jun; 29():108-119. PubMed ID: 37021039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia.
    Haring MPD; Peeks F; Oosterveer MH; Brouwers MCGJ; Hollak CEM; Janssen MCH; Langendonk JG; Rennings AJM; Wagenmakers MAEM; Verkade HJ; Derks TGJ; de Meijer VE
    JHEP Rep; 2022 Aug; 4(8):100512. PubMed ID: 35811762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acoustic accessibility investigation for ultrasound mediated treatment of glycogen storage disease type Ia patients.
    Wang S; Raju BI; Leyvi E; Weinstein DA; Seip R
    Ultrasound Med Biol; 2011 Sep; 37(9):1469-77. PubMed ID: 21767906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.